Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
DIP, 10% Decrease in Ordinary Profit for The Current Fiscal Year
2379 DIP corporation 【J-GAAP】
Earnings ReportDIP corporation <2379> [TSE Prime] announced its financial results after the market closed on April 14th (15:30). The consolidated ordinary profit for the fiscal year ending February 2025 increased 5.1% from the previous period to 13.2 billion yen. However, for the fiscal year ending February 2026, the profit is expected to decrease by 10.2% from the previous period to 11.9 billion yen.
In the most recent three-month period, from December to February (4Q), the consolidated ordinary profit decreased to 2.47 billion yen, a 15.0% decrease compared to the same period last year. The operating profit margin decreased from 21.8% in the same period last year to 18.4%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2023 | 49,355 | 11,538 | 11,599 | 7,935 | 142.0 | 72 | Apr 14, 2023 | J-GAAP |
Feb, 2024 | 53,782 | 12,761 | 12,618 | 9,050 | 163.4 | 88 | Apr 12, 2024 | J-GAAP |
Feb, 2025 | 56,386 | 13,405 | 13,257 | 8,951 | 168.4 | 95 | Apr 14, 2025 | J-GAAP |
YoY | +4.8% | +5.0% | +5.1% | -1.1% | +3.0% |
Full Year Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2025 Guidance | 57,600 | 13,400 | 13,200 | 8,900 | 170.1 | 95 | Oct 15, 2024 | J-GAAP |
Feb, 2025 Results | 56,386 | 13,405 | 13,257 | 8,951 | 168.4 | 95 | Apr 14, 2025 | J-GAAP |
Revision Rate | -2.1% | +0.0% | +0.4% | +0.6% | -1.0% |
Current Period Guidance
H1 Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar - Aug, 2024 | 28,424 | 7,516 | 7,420 | 5,046 | 93.5 | 47 | Oct 15, 2024 | J-GAAP |
Mar - Aug, 2025 Guidance | ー | ー | ー | ー | - | 47 | Apr 14, 2025 | J-GAAP |
YoY | - | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2024 | 53,782 | 12,761 | 12,618 | 9,050 | 163.4 | 88 | Apr 12, 2024 | J-GAAP |
Feb, 2025 | 56,386 | 13,405 | 13,257 | 8,951 | 168.4 | 95 | Apr 14, 2025 | J-GAAP |
Feb, 2026 Guidance | 60,000 | 12,000 | 11,900 | 8,000 | 152.9 | 95 | Apr 14, 2025 | J-GAAP |
YoY | +6.4% | -10.5% | -10.2% | -10.6% | -9.2% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - Feb, 2023 | 13,527 | 2,943 | 2,909 | 2,220 | 40.1 | 21.8 | Apr 12, 2024 | J-GAAP |
Mar - May, 2024 | 15,279 | 4,023 | 3,997 | 2,804 | 51.4 | 26.3 | Jul 9, 2024 | J-GAAP |
Jun - Aug, 2024 | 13,145 | 3,493 | 3,423 | 2,242 | 41.6 | 26.6 | Oct 15, 2024 | J-GAAP |
Sep - Nov, 2024 | 14,228 | 3,365 | 3,363 | 2,315 | 43.3 | 23.7 | Jan 14, 2025 | J-GAAP |
Dec - Feb, 2024 | 13,734 | 2,524 | 2,474 | 1,590 | 29.9 | 18.4 | Apr 14, 2025 | J-GAAP |
YoY | +1.5% | -14.2% | -15.0% | -28.4% | -25.4% |
Related Articles
DEMAE-CAN, First Half Ordinary Profit Loss Narrows, Dec-Feb Ordinary Profit Loss Narrows
Copa Corp, Net Income/Loss Unexpectedly Turn to Loss for Last Fiscal Year, The Current Fiscal Year's Net Income to Narrow
STUDIO ALICE, 6% Decrease in Ordinary Profit for The Current Fiscal Year
COSMOS Pharma, Jun-Feb (Cumulative 3Q) Ordinary Profit Increases by 30%, Dec-Feb Ordinary Profit Increases by 40%
FP Partner, Dec-Feb (1Q) Ordinary Profit Decreases by 42%
Totenko, 2% Increase in Ordinary Profit for The Current Fiscal Year
Asterisk, The Current Fiscal Year Ordinary Profit Revised Downward by 82%
Maruto Sangyo, 15% Increase in Ordinary Profit for The Current Fiscal Year
VALUE CREATION, 50% Increase in Ordinary Profit, Record High for The First Time in Two Years, Dividend Raised by 0.5 yen
Daito Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 26%